Mary Mehlig
Enzon Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, RNA Interference and Gene Delivery, Radiopharmaceutical Chemistry and Applications, Lung Cancer Treatments and Mutations, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Structure−Function Engineering of Interferon-β-1b for Improving Stability, Solubility, Potency, Immunogenicity, and Pharmacokinetic Properties by Site-Selective Mono-PEGylation(2006)213 cited
- → Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model(2008)165 cited
- → Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation(2003)118 cited
- → Antitumor activity of poly(ethylene glycol)–camptothecin conjugate: The inhibition of tumor growth in vivo(2005)116 cited
- → Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C.II. Efficacy in ascites and solid tumors(2002)77 cited
- → Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects(2011)66 cited
- → Engineering an Arginine Catabolizing Bioconjugate: Biochemical and Pharmacological Characterization of PEGylated Derivatives of Arginine Deiminase from Mycoplasma arthritidis(2006)27 cited
- → Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphoma(2009)25 cited
- → Delivery of G3139 using releasable PEG-linkers: Impact on pharmacokinetic profile and anti-tumor efficacy(2006)20 cited
- → Marked Therapeutic Efficacy of a Novel Polyethyleneglycol-SN38 Conjugate, EZN-2208, in Xenograft Models of Non-Hodgkin’s Lymphoma.(2007)1 cited